IDEAYA Biosciences (IDYA) Corporate presentation summary

Vision and strategy

• Aims to be a leader in precision medicine oncology, focusing on first- and best-in-class programs using predictive biomarkers and AI-driven drug discovery.

• Pipeline targets rational combinations and multiple solid tumor indications, including neoadjuvant, adjuvant, and first-line metastatic disease.

Drug discovery platform

• Six internally discovered clinical-stage molecules address challenging targets like helicases, polymerases, and glycohydrolases.

• Utilizes CRISPR-based target discovery, chemigenomics, and AI-driven drug design for accelerated IND delivery.

• Achieves novel selectivity profiles and leverages proprietary structural data for computational drug discovery.

Clinical pipeline highlights

• Darovasertib targets uveal melanoma (UM) with a unique PKC inhibition mechanism, showing significant efficacy in both primary and metastatic UM.

• IDE849 (DLL3 ADC) and IDE161 (PARG inhibitor) show synergy in preclinical models, with IDE849 demonstrating robust responses in SCLC.

• IDE034 (B7H3/PTK7 bispecific ADC) and IDE397 (MAT2A inhibitor) expand the pipeline into additional solid tumor indications.